Common Heartburn Drug Studied As COVID-19 Treatment

The video discusses a study at Northwell Health hospitals in New York City, where patients are receiving higher doses of Famotidine, the active ingredient in Pepcid, to treat COVID-19. The study is based on an unpublished Chinese report suggesting potential benefits. Some patients are also receiving hydroxychloroquine, previously touted by President Trump as a 'Game Changer.' However, recent studies suggest hydroxychloroquine may be ineffective, leading to hesitancy in promoting trials to avoid a run on heartburn medication. Dr. Kevin Tracy emphasizes the need for clinical trials to determine Famotidine's efficacy.

What new insight or understanding did you gain from this video?